Semaglutide® providers &
prescriptions in Reading, PA
Verified Semaglutide providers in Reading, PA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find a Semaglutide provider in Pennsylvania.
Every entry is checked against the NPI registry and the Pennsylvania medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Semaglutide in Reading.
33 GLP-1 prescribers and 7 local resource types are on record for Reading, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Pennsylvania’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.
Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]
In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]
Community health · CDC
Weight & metabolic health in Reading
Reading, Pennsylvania has a population of 95,112 people. The adult obesity rate in Reading is an age-adjusted estimate of 43.3%, 9.1 percentage points above the Pennsylvania state rate of 34.2%. Diagnosed diabetes reaches 16.2% of adults in Reading. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 38.4% of adults in Reading.
- of Reading adults have obesity
- 43.3%
- diagnosed diabetes
- 16.2%
- no regular physical activity
- 38.4%
Age-adjusted estimates for Reading, community figures, not individual risk. CDC PLACES, 2024 release.
The prescription is one part. Here is the rest, in Reading.
Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Reading, PA, ordered as the registry lists them, never by who pays us.
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
6Th Avenue & Spruce Street
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
3933 Perkiomen Ave Ste 104
What the trials actually showed.
We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]